Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651450 | PMC |
| http://dx.doi.org/10.1016/j.esmoop.2023.102049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.
J Exp Clin Cancer Res
November 2024
Clinical Trial Center, Translational Research and Phase I Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.
Among blood cancers, multiple myeloma (MM) represents the second most common neoplasm and is characterized by the accumulation and proliferation of monoclonal plasma cells within the bone marrow. Despite the last few decades being characterized by the development of different therapeutic strategies against MM, at present such disease is still considered incurable. Although MM is highly heterogeneous in terms of genetic and molecular subtypes, about 67% of MM cases are associated with abnormal activity of the transcription factor c-Myc, which has so far revealed a protein extremely difficult to target.
View Article and Find Full Text PDFWhat Is This Summary About?: This summary describes the results from a phase 2 study called FOENIXCCA2. The study evaluated treatment with futibatinib in people with a rare form of advanced bile duct cancer called intrahepatic cholangiocarcinoma (or iCCA), where the tumors have changes in the structure of a gene called FGFR2. These changes include FGFR2 gene fusions.
View Article and Find Full Text PDFFutibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.
ESMO Open
December 2023
Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada; Medical Oncology, Margaret Cancer Centre, Toronto, Canada.
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments.
Cancers (Basel)
September 2023
Medical Oncology Department, Gustave Roussy, F-94805 Villejuif, France.
Biliary tract cancers (BTCs) are rare tumours, most often diagnosed at an unresectable stage, associated with poor prognosis, with a 5-year survival rate not exceeding 10%. Only first- and second-line treatments are well codified with the combination of cisplatin-gemcitabine chemotherapy and immunotherapy followed by 5-FU and oxaliplatin chemotherapy, respectively. Many studies have shown that BTC, and more particularly intrahepatic cholangiocarcinoma (iCCA), have a high rate of targetable somatic alteration.
View Article and Find Full Text PDFUpdates in the use of targeted therapies for the treatment of cholangiocarcinoma.
J Oncol Pharm Pract
July 2023
Department of Pharmacy, UF Health Shands Hospital, Gainesville, FL, USA.
Article Synopsis
- - The text discusses the current treatment landscape for cholangiocarcinoma (CCA), emphasizing that many patients are not surgical candidates and survival with traditional chemotherapy is under 12 months.
- - A systematic review identified four FDA-approved targeted therapies for advanced CCA, including ivosidenib and three FGFR2 inhibitors, which have created new options for treatment and improved patient outcomes.
- - The emergence of these targeted therapies has prompted new research into combination treatments, such as integrating chemotherapy and immunotherapy, enhancing the overall approach to managing CCA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!